Abstract:Background. In vitro experiments from multiple laboratories have shown that the methylation-induced silencing of the p16INK4A gene, a tumor suppressor gene, can be reversed by DNA methyltransferase (DNMT1) inhibitor-based epigenetic modulation. However, it remains unclear whether DNMT1 inhibitors induce re-expression of p16INK4A in patients treated with demethylation promoting agents. Here we report p16INK4A expression status in human circulating tumor cells (CTCs) and its dynamic changes during DNMT1 inhibitor therapy in patients with advanced solid tumors, by using a novel CTC-based p16INK4A immunofluorescence assay. Methods. We demonstrated in vitro re-expression of p16 by Western blot and whole cell immunofluorescence in EJ-6 cells treated with decitabine, 4-thio-2’-deoxycytidine (TdCyd) and 5-fluoro-2’-deoxyctidine (FdC) but not in the p16-deleted line A549. We analyzed p16 re-expression in epithelial /mesenchymal CTC subpopulations as a clinical pharmacodynamic (PD) marker to assess the effects of DNMT1 inhibitors (analyzed using CellSearch® and fluorescence microscopy). Results. Over 300 specimens from 70 patients were analyzed from patients enrolled in both Phase 1 and Phase 2 clinical trials of the DNMT1 inhibitors TdCyd or FdC in combination with tetrahydrouridine (THU). Circulating tumor cells were characterized as DAPI+/CD45-/CEA or MUC1 positive, then classified as epithelial or mesenchymal based on expression of (pan-)cytokeratin (CK) or vimentin (VIM), respectively. The p16INK4A-positive CTC baseline level ranged from 0 to 15% in 57 of 58 patients with assessable CK+CTC numbers and in 46 of 53 patients with assessable VIM+CTC numbers. There were no patient specimens with CTCs that were positive for only VIM, but most specimens had higher numbers of VIM+ CTC compared to CK+ CTC, and not all patients had both CTC phenotypes present at baseline. During treatment with DNMT1 inhibitors, p16INK4A-positive CTCs increased in 46 of 58 patients with assessable CK+ CTCs (epithelial phenotype), but only 6 patients with VIM+ CTCs (mesenchymal phenotype) had p16 re-expression, and these patients had both CTC phenotypes present. The restoration of p16INK4A expression in CTC, not the CTC number, was correlated with evidence of drug clinical activity in patients. Drug treatment longer than 2 cycles was associated with both EMT phenotypic conversion and obvious morphological changes in CTCs that accompanied increased p16INK4A expression. Conclusions. Our studies indicate that monitoring dynamic changes of CTC-based p16INK4A expression is a sensitive PD biomarker for assessing DNMT1-targeted epigenetic anticancer therapeutics in clinical development. CTCs were predominantly mesenchymal phenotype. In addition, the CTC phenotype (epithelial vs mesenchymal) appeared to be quite dynamic in treated patients. Funded by NCI Contract No. HHSN261200800001E, and Cooperative Agreements U01CA062505 and UM1CA186717. Citation Format: Lihua Wang, Brandon Miller, Sonny Khin, Geraldine O’Sullivan-Coyne, Alice P. Chen, Shivaani Kummar, Naoko Takebe, Kate Ferry-Galow, Ralph E. Parchment, Larry Rubinstein, Richard Piekarz, Edward M. Newman, James H. Doroshow, Robert J. Kinders. Restoration of p16INK4A expression in circulating tumor cells in patients with advanced solid tumors treated with deoxycytidine analogs and associated dynamic EMT phenotypic changes [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B018. doi:10.1158/1535-7163.TARG-19-B018

In Vitro Tumor Suppression of p16INK4a

Changes of Biophysical Behavior of K562 Cells for P16 Gene Transfer.

Wild-Type P16(Ink4a) Suppresses Cell Growth, Telomerase Activity And Dna Repair In Human Breast Cancer Mcf-7 Cells

The Study of the Inhibitory Effect of Anti-Oncogene P16 on the Proliferation of Human Cholangiocarcinoma Cell Line

P16 Suppressor Gene and Tumor

Posttranscriptional Induction of P21waf1 Mediated by Ectopic P16ink4 in Human Diploid Fibroblast

Restoration of the p16 gene is related to increased radiosensitivity of p16 -deficient lung adenocarcinoma cell lines

Adenovirus-mediated Transfer of P53 and P16 Inhibiting Proliferating Activity of Human Bladder Cancer Cell EJ in Vitro and in Vivo

Systemic transduction of p16INK4A antitumor peptide inhibits the growth of MBT-2 mouse bladder tumor cell line grafts.

Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis

Study on the Relationship Between P16ink4a and Cervical Cancer

The Effect of Anti-Oncogene P15, P16 on the Proliferation of a Human Cholangio Carcinoma Cell Line

The Inhibition of Laryngeal Cancer Cell (hep -2) by P16 Gene Mediated with Non - Viral GE7 Polypeptide Delivery System

P16 Gene Expression Mediated by Adenovirus and Its Effect on Cell Cycle Arrest

Proliferative and Invasive Effects of Inhibitors of Kinase 4 (p15ink4b and P16ink4a/CDKN2) Gene Activation on RKO Human Colorectal Cancer Cells

P16 Promotes the Growth and Mobility Potential of Breast Cancer Both in Vitro and in Vivo: the Key Role of the Activation of IL-6/JAK2/STAT3 Signaling

P16 Promotes Proliferation in Cervical Carcinoma Cells Through CDK6-HuR-IL1A Axis

Abstract B018: Restoration of p16INK4Aexpression in circulating tumor cells in patients with advanced solid tumors treated with deoxycytidine analogs and associated dynamic EMT phenotypic changes

In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.

Induction of senescence in human malignant glioma cells by p16INK4A

Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition